Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
8.12M | 8.55M | 2.45M | 0.00 | 0.00 | 0.00 | Gross Profit |
7.97M | 8.20M | 2.45M | -1.17M | -1.59M | -746.00K | EBIT |
-233.01M | -200.16M | -126.37M | -214.99M | -167.33M | -61.97M | EBITDA |
-232.87M | -200.16M | -125.94M | -212.86M | -165.47M | -61.08M | Net Income Common Stockholders |
-212.56M | -182.82M | -123.28M | -213.07M | -166.88M | -61.82M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
327.99M | 392.57M | 81.30M | 100.49M | 275.91M | 296.61M | Total Assets |
478.74M | 483.11M | 87.95M | 115.13M | 292.75M | 303.18M | Total Debt |
1.07M | 1.37M | 2.50M | 4.50M | 4.31M | 763.00K | Net Debt |
-164.50M | -214.00M | -78.81M | -57.11M | -134.39M | -295.85M | Total Liabilities |
39.52M | 37.66M | 18.28M | 39.02M | 41.94M | 15.72M | Stockholders Equity |
439.21M | 445.45M | 69.67M | 76.11M | 250.81M | 287.46M |
Cash Flow | Free Cash Flow | ||||
-163.85M | -131.76M | -111.19M | -185.49M | -125.60M | -52.62M | Operating Cash Flow |
-163.91M | -131.76M | -111.14M | -185.04M | -124.55M | -52.62M | Investing Cash Flow |
-208.34M | -248.49M | 38.95M | 96.89M | -140.52M | 4.00K | Financing Cash Flow |
385.83M | 514.32M | 91.87M | 10.46M | 107.59M | 304.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $744.72M | ― | 222.83% | ― | 29.88% | 35.11% | |
54 Neutral | $774.97M | 166.39 | 11.62% | ― | ― | ― | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
52 Neutral | $650.50M | ― | -33.48% | ― | -25.88% | -29.16% | |
51 Neutral | $796.56M | ― | -57.92% | ― | -13.37% | 2.57% | |
50 Neutral | $839.20M | ― | -63.56% | ― | 270.02% | 32.69% | |
45 Neutral | $833.64M | ― | -119.66% | ― | ― | -551.08% |
On May 2, 2025, Praxis Precision Medicines updated its corporate presentation and provided significant updates on its developmental programs at an investor event. Notably, the company shared promising data from the EMBOLD study, showing sustained seizure reduction in patients with SCN2A and SCN8A DEEs treated with relutrigine. Additionally, Praxis announced the trial design for the EMERALD study, a Phase 3 clinical trial evaluating relutrigine in a broader DEE patient population. The company also plans to nominate a development candidate for its PRAX-100 program targeting SCN2A loss-of-function mutations by mid-2025. These updates reflect Praxis’s ongoing efforts to advance its pipeline and strengthen its position in the CNS disorder treatment market.